Evaluation of a new Swedish protocol for alloimmunization screening during pregnancy
Screening protocols for alloimmunization during pregnancy usually make a difference between primi- and multigravidae as well as between Rh(D) negative and Rh(D) positive pregnant women. We have evaluated a new screening program including antibody tests at 25 and 35 gestational weeks only, for all, a...
Gespeichert in:
| Veröffentlicht in: | Acta obstetricia et gynecologica Scandinavica 1993-08, Vol.72 (6), p.434-438 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 438 |
|---|---|
| container_issue | 6 |
| container_start_page | 434 |
| container_title | Acta obstetricia et gynecologica Scandinavica |
| container_volume | 72 |
| creator | Gottvall, Tomas Selbing, Anders Hilden, Jan-Olof |
| description | Screening protocols for alloimmunization during pregnancy usually make a difference between primi- and multigravidae as well as between Rh(D) negative and Rh(D) positive pregnant women. We have evaluated a new screening program including antibody tests at 25 and 35 gestational weeks only, for all, and regardless of Rh(D) group. During the time period 1983-89, 78,300 consecutive pregnancies were tested. Red cell antibody immunizations were detected in 287 (0.37%) pregnancies subdivided into fourteen different red cell IgG antibody specificities. Significant antibody titers (defined as IAT or enzyme titers ≤8) were observed in 225 pregnancies, where 127 (56%) were previously unknown. A majority (63%) of the new immunizations occurred among the Rh(D) positive pregnant women. All newborns that needed phototherapy or exchange transfusion due to alloimmunization were recognized at the time of delivery. We conclude that antibody screening tests at 25 and 35 gestational weeks for both Rh(D) negative and positive pregnant women is sufficient, effective and a safe procedure for the fetus as well as for the mother. |
| doi_str_mv | 10.3109/00016349309021130 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75892456</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75892456</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4625-3d1c6706c8100299e48a42785469115b52f094b0677d44c5e9adeb1d187b9383</originalsourceid><addsrcrecordid>eNqFkU2P0zAQhi0EWsrCD-CAlAPiFhgn_ojFabUfBal0D1TiaDmOs_Xi2MVuKOXX4ypRL0hwGlnv88543kHoNYb3NQbxAQAwq4moQUCFcQ1P0AIzgBIIrp6ixUkvT8Bz9CKlx_yqOGku0EVTC8IqWKDN7U_lRrW3wRehL1ThzaH4ejCdTdtiF8M-6OCKPsRCORfsMIze_p7wpKMx3vqHohvjqeyiefDK6-NL9KxXLplXc71Em7vbzfWncnW__Hx9tSp1Hk7LusOacWC6wQCVEIY0ilS8oYQJjGlLqx4EaYFx3hGiqRGqMy3ucMNbUTf1JXo3tc3__DGatJeDTdo4p7wJY5KcNqIilGUQT6COIaVoermLdlDxKDHIU5DyryCz583cfGwH050dc3JZfzvrKmnl-pgXt-mMkSYHzXDG2IQdrDPH_8-VV_dLTjHNxnIy2rQ3v85GFb9LxmtO5bf1Ut5VdA03qy9ynfmPM-_ztQa1Ncrtt1pFIx_DGH2-wz-2_QM-b6ox</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75892456</pqid></control><display><type>article</type><title>Evaluation of a new Swedish protocol for alloimmunization screening during pregnancy</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Gottvall, Tomas ; Selbing, Anders ; Hilden, Jan-Olof</creator><creatorcontrib>Gottvall, Tomas ; Selbing, Anders ; Hilden, Jan-Olof</creatorcontrib><description>Screening protocols for alloimmunization during pregnancy usually make a difference between primi- and multigravidae as well as between Rh(D) negative and Rh(D) positive pregnant women. We have evaluated a new screening program including antibody tests at 25 and 35 gestational weeks only, for all, and regardless of Rh(D) group. During the time period 1983-89, 78,300 consecutive pregnancies were tested. Red cell antibody immunizations were detected in 287 (0.37%) pregnancies subdivided into fourteen different red cell IgG antibody specificities. Significant antibody titers (defined as IAT or enzyme titers ≤8) were observed in 225 pregnancies, where 127 (56%) were previously unknown. A majority (63%) of the new immunizations occurred among the Rh(D) positive pregnant women. All newborns that needed phototherapy or exchange transfusion due to alloimmunization were recognized at the time of delivery. We conclude that antibody screening tests at 25 and 35 gestational weeks for both Rh(D) negative and positive pregnant women is sufficient, effective and a safe procedure for the fetus as well as for the mother.</description><identifier>ISSN: 0001-6349</identifier><identifier>EISSN: 1600-0412</identifier><identifier>DOI: 10.3109/00016349309021130</identifier><identifier>PMID: 8394620</identifier><identifier>CODEN: AOGSAE</identifier><language>eng</language><publisher>Oxford, UK: Informa UK Ltd</publisher><subject>alloimmunization in pregnancy ; antibody screening ; Biological and medical sciences ; Coombs Test ; Diseases of mother, fetus and pregnancy ; epidemiology ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Immunoglobulin G - blood ; Infant, Newborn ; Infant, Newborn, Diseases - therapy ; Mass Screening ; Medical sciences ; Postpartum Period ; Pregnancy ; Pregnancy Complications - blood ; Pregnancy Complications - epidemiology ; Pregnancy Complications - prevention & control ; Pregnancy. Fetus. Placenta ; Rh Isoimmunization - blood ; Rh Isoimmunization - epidemiology ; Rh Isoimmunization - prevention & control ; Rh-Hr Blood-Group System ; Sweden - epidemiology</subject><ispartof>Acta obstetricia et gynecologica Scandinavica, 1993-08, Vol.72 (6), p.434-438</ispartof><rights>1993 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1993</rights><rights>1993 Acta Obstet Gynecol Scand</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4625-3d1c6706c8100299e48a42785469115b52f094b0677d44c5e9adeb1d187b9383</citedby><cites>FETCH-LOGICAL-c4625-3d1c6706c8100299e48a42785469115b52f094b0677d44c5e9adeb1d187b9383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.3109%2F00016349309021130$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.3109%2F00016349309021130$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4874861$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8394620$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gottvall, Tomas</creatorcontrib><creatorcontrib>Selbing, Anders</creatorcontrib><creatorcontrib>Hilden, Jan-Olof</creatorcontrib><title>Evaluation of a new Swedish protocol for alloimmunization screening during pregnancy</title><title>Acta obstetricia et gynecologica Scandinavica</title><addtitle>Acta Obstet Gynecol Scand</addtitle><description>Screening protocols for alloimmunization during pregnancy usually make a difference between primi- and multigravidae as well as between Rh(D) negative and Rh(D) positive pregnant women. We have evaluated a new screening program including antibody tests at 25 and 35 gestational weeks only, for all, and regardless of Rh(D) group. During the time period 1983-89, 78,300 consecutive pregnancies were tested. Red cell antibody immunizations were detected in 287 (0.37%) pregnancies subdivided into fourteen different red cell IgG antibody specificities. Significant antibody titers (defined as IAT or enzyme titers ≤8) were observed in 225 pregnancies, where 127 (56%) were previously unknown. A majority (63%) of the new immunizations occurred among the Rh(D) positive pregnant women. All newborns that needed phototherapy or exchange transfusion due to alloimmunization were recognized at the time of delivery. We conclude that antibody screening tests at 25 and 35 gestational weeks for both Rh(D) negative and positive pregnant women is sufficient, effective and a safe procedure for the fetus as well as for the mother.</description><subject>alloimmunization in pregnancy</subject><subject>antibody screening</subject><subject>Biological and medical sciences</subject><subject>Coombs Test</subject><subject>Diseases of mother, fetus and pregnancy</subject><subject>epidemiology</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunoglobulin G - blood</subject><subject>Infant, Newborn</subject><subject>Infant, Newborn, Diseases - therapy</subject><subject>Mass Screening</subject><subject>Medical sciences</subject><subject>Postpartum Period</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - blood</subject><subject>Pregnancy Complications - epidemiology</subject><subject>Pregnancy Complications - prevention & control</subject><subject>Pregnancy. Fetus. Placenta</subject><subject>Rh Isoimmunization - blood</subject><subject>Rh Isoimmunization - epidemiology</subject><subject>Rh Isoimmunization - prevention & control</subject><subject>Rh-Hr Blood-Group System</subject><subject>Sweden - epidemiology</subject><issn>0001-6349</issn><issn>1600-0412</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2P0zAQhi0EWsrCD-CAlAPiFhgn_ojFabUfBal0D1TiaDmOs_Xi2MVuKOXX4ypRL0hwGlnv88543kHoNYb3NQbxAQAwq4moQUCFcQ1P0AIzgBIIrp6ixUkvT8Bz9CKlx_yqOGku0EVTC8IqWKDN7U_lRrW3wRehL1ThzaH4ejCdTdtiF8M-6OCKPsRCORfsMIze_p7wpKMx3vqHohvjqeyiefDK6-NL9KxXLplXc71Em7vbzfWncnW__Hx9tSp1Hk7LusOacWC6wQCVEIY0ilS8oYQJjGlLqx4EaYFx3hGiqRGqMy3ucMNbUTf1JXo3tc3__DGatJeDTdo4p7wJY5KcNqIilGUQT6COIaVoermLdlDxKDHIU5DyryCz583cfGwH050dc3JZfzvrKmnl-pgXt-mMkSYHzXDG2IQdrDPH_8-VV_dLTjHNxnIy2rQ3v85GFb9LxmtO5bf1Ut5VdA03qy9ynfmPM-_ztQa1Ncrtt1pFIx_DGH2-wz-2_QM-b6ox</recordid><startdate>199308</startdate><enddate>199308</enddate><creator>Gottvall, Tomas</creator><creator>Selbing, Anders</creator><creator>Hilden, Jan-Olof</creator><general>Informa UK Ltd</general><general>Blackwell Publishing Ltd</general><general>Taylor & Francis</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199308</creationdate><title>Evaluation of a new Swedish protocol for alloimmunization screening during pregnancy</title><author>Gottvall, Tomas ; Selbing, Anders ; Hilden, Jan-Olof</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4625-3d1c6706c8100299e48a42785469115b52f094b0677d44c5e9adeb1d187b9383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>alloimmunization in pregnancy</topic><topic>antibody screening</topic><topic>Biological and medical sciences</topic><topic>Coombs Test</topic><topic>Diseases of mother, fetus and pregnancy</topic><topic>epidemiology</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunoglobulin G - blood</topic><topic>Infant, Newborn</topic><topic>Infant, Newborn, Diseases - therapy</topic><topic>Mass Screening</topic><topic>Medical sciences</topic><topic>Postpartum Period</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - blood</topic><topic>Pregnancy Complications - epidemiology</topic><topic>Pregnancy Complications - prevention & control</topic><topic>Pregnancy. Fetus. Placenta</topic><topic>Rh Isoimmunization - blood</topic><topic>Rh Isoimmunization - epidemiology</topic><topic>Rh Isoimmunization - prevention & control</topic><topic>Rh-Hr Blood-Group System</topic><topic>Sweden - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gottvall, Tomas</creatorcontrib><creatorcontrib>Selbing, Anders</creatorcontrib><creatorcontrib>Hilden, Jan-Olof</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta obstetricia et gynecologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gottvall, Tomas</au><au>Selbing, Anders</au><au>Hilden, Jan-Olof</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of a new Swedish protocol for alloimmunization screening during pregnancy</atitle><jtitle>Acta obstetricia et gynecologica Scandinavica</jtitle><addtitle>Acta Obstet Gynecol Scand</addtitle><date>1993-08</date><risdate>1993</risdate><volume>72</volume><issue>6</issue><spage>434</spage><epage>438</epage><pages>434-438</pages><issn>0001-6349</issn><eissn>1600-0412</eissn><coden>AOGSAE</coden><abstract>Screening protocols for alloimmunization during pregnancy usually make a difference between primi- and multigravidae as well as between Rh(D) negative and Rh(D) positive pregnant women. We have evaluated a new screening program including antibody tests at 25 and 35 gestational weeks only, for all, and regardless of Rh(D) group. During the time period 1983-89, 78,300 consecutive pregnancies were tested. Red cell antibody immunizations were detected in 287 (0.37%) pregnancies subdivided into fourteen different red cell IgG antibody specificities. Significant antibody titers (defined as IAT or enzyme titers ≤8) were observed in 225 pregnancies, where 127 (56%) were previously unknown. A majority (63%) of the new immunizations occurred among the Rh(D) positive pregnant women. All newborns that needed phototherapy or exchange transfusion due to alloimmunization were recognized at the time of delivery. We conclude that antibody screening tests at 25 and 35 gestational weeks for both Rh(D) negative and positive pregnant women is sufficient, effective and a safe procedure for the fetus as well as for the mother.</abstract><cop>Oxford, UK</cop><pub>Informa UK Ltd</pub><pmid>8394620</pmid><doi>10.3109/00016349309021130</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-6349 |
| ispartof | Acta obstetricia et gynecologica Scandinavica, 1993-08, Vol.72 (6), p.434-438 |
| issn | 0001-6349 1600-0412 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75892456 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | alloimmunization in pregnancy antibody screening Biological and medical sciences Coombs Test Diseases of mother, fetus and pregnancy epidemiology Female Gynecology. Andrology. Obstetrics Humans Immunoglobulin G - blood Infant, Newborn Infant, Newborn, Diseases - therapy Mass Screening Medical sciences Postpartum Period Pregnancy Pregnancy Complications - blood Pregnancy Complications - epidemiology Pregnancy Complications - prevention & control Pregnancy. Fetus. Placenta Rh Isoimmunization - blood Rh Isoimmunization - epidemiology Rh Isoimmunization - prevention & control Rh-Hr Blood-Group System Sweden - epidemiology |
| title | Evaluation of a new Swedish protocol for alloimmunization screening during pregnancy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T21%3A46%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20a%20new%20Swedish%20protocol%20for%20alloimmunization%20screening%20during%20pregnancy&rft.jtitle=Acta%20obstetricia%20et%20gynecologica%20Scandinavica&rft.au=Gottvall,%20Tomas&rft.date=1993-08&rft.volume=72&rft.issue=6&rft.spage=434&rft.epage=438&rft.pages=434-438&rft.issn=0001-6349&rft.eissn=1600-0412&rft.coden=AOGSAE&rft_id=info:doi/10.3109/00016349309021130&rft_dat=%3Cproquest_cross%3E75892456%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75892456&rft_id=info:pmid/8394620&rfr_iscdi=true |